Description de l'entreprise
PharmaSGP is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter (“OTC”) and other healthcare products. PharmaSGP’s products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and fewer known side effects than most chemical-based pharmaceuticals. The Company’s core brands cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RUBAXX® for rheumatic pain and RESTAXIL® for neuralgic pain. Furthermore, PharmaSGP has introduced leading products against sexual weakness and vertigo symptoms.
Conseil d'administration & Conseil de surveillance
| PDG |
| Natalie Weigand |
| Conseil d'administration |
| Michael Rudolf |
| Conseil de surveillance |
| Dr. Clemens Fischer, Madlena Hohlefelder, Dr. Axel Rebien |
Données de l'entreprise
| Nom: |
PharmaSGP Holding SE |
| Adresse: |
Lochhamer Schlag 21,D-82166 Gräfelfing |
| Téléphone: |
+49-611-2058-5528 |
| Fax: |
+49-611-2058-5566 |
| Courriel: |
info@pharmasgp.com
|
| Internet: |
https://pharmasgp.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
19/06/2020 |
Relations avec les investisseurs
| Nom: |
Claudius Krause |
| Téléphone IR: |
+49-611-2058-5535 |
| IR-Fax: |
- |
| E-mail IR: |
ir@pharmasgp.com
|
